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Abstract
Background: Nutrition is believed to be a primary contributor in regulating gene expression by affecting epigenetic
pathways such as DNA methylation and histone modification. Resveratrol and pterostilbene are phytoalexins produced
by plants as part of their defense system. These two bioactive compounds when used alone have been shown to alter
genetic and epigenetic profiles of tumor cells, but the concentrations employed in various studies often far exceed
physiologically achievable doses. Triple-negative breast cancer (TNBC) is an often fatal condition that may be prevented
or treated through novel dietary-based approaches.
Methods: HCC1806 and MDA-MB-157 breast cancer cells were used as TNBC cell lines in this study. MCF10A cells were
used as control breast epithelial cells to determine the safety of this dietary regimen. CompuSyn software was used to
determine the combination index (CI) for drug combinations.
Results: Combinatorial resveratrol and pterostilbene administered at close to physiologically relevant doses resulted
in synergistic (CI <1) growth inhibition of TNBCs. SIRT1, a type III histone deacetylase (HDAC), was down-regulated in
response to this combinatorial treatment. We further explored the effects of this novel combinatorial approach on DNA
damage response by monitoring γ-H2AX and telomerase expression. With combination of these two compounds there
was a significant decrease in these two proteins which might further resulted in significant growth inhibition, apoptosis
and cell cycle arrest in HCC1806 and MDA-MB-157 breast cancer cells, while there was no significant effect on cellular
viability, colony forming potential, morphology or apoptosis in control MCF10A breast epithelial cells. SIRT1 knockdown
reproduced the effects of combinatorial resveratrol and pterostilbene-induced SIRT1 down-regulation through inhibition of
both telomerase activity and γ-H2AX expression in HCC1806 breast cancer cells. As a part of the repair mechanisms and
role of SIRT1 in recruiting DNMTs, the effects of this combination treatment was also explored on DNA methyltransferases
(DNMTs) expression. Interestingly, the compounds resulted in a significant down-regulation of DNMT enzymes with no
significant effects on DNMT enzyme expression in MCF10A control cells.
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Conclusion: Collectively, these results provide new insights into the epigenetic mechanisms of a novel combinatorial
nutrient control strategy that exhibits synergy and may contribute to future recalcitrant TNBC prevention and/or therapy.
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Background
Breast cancer is among the most common cancers of
women in the United States, second only to skin cancer.
After lung cancer, it is the second leading cause of can-
cer death in women. Currently, an estimate of 231,840
new cases of invasive breast cancer are expected to be
diagnosed and about 40,290 breast cancer deaths in women
are expected in the year 2015 [1]. Out of the total breast
cancers, around 10–20 % of breast cancer are designated as
triple-negative breast cancers (TNBC). They lack potential
biomarkers such as endocrine receptors: estrogen and pro-
gesterone receptors (ER and PR, respectively) and HER2
protein. They are typically associated with a poor prognosis
and are recalcitrant to conventional hormonal therapies, in
contrast to triple-positive breast cancers and HER2-positive
breast cancers. Epidemiological studies have indicated that
the incidence rate of cancers is higher in affluent nations
where the diet and the environment contribute to genomic
instabilities [2, 3]. In many developing countries, such as
those in Asia where fruits and vegetables are the staple diet,
incidences of cancer are remarkably lower [4]. Cancer has
been viewed as a set of diseases that are driven by pro-
gressive genetic abnormalities as well as epigenetic al-
terations [5].
Diet-or environment-induced aberrations of genes may
develop over time but are often reversible, indicating that
only gene expression has changed while the actual DNA
sequence remains unchanged. Such reversible gene-based
alterations are mediated by a process referred to as epi-
genetics. Epigenetic changes are believed to occur at a
higher frequency than sequence-based genetic changes.
The common epigenetic modifications that occur are
DNA methylation, histone modifications such as acetyl-
ation, methylation and phosphorylation, and chromatin
remodeling. DNA methylation and histone modification
play important roles in the transcriptional regulation of
genes involved in cell cycle progression, proliferation,
apoptosis, and cell death. Alterations in the epigenetic-
controlled expression of these genes may mediate carcino-
genic processes as well. This paper will focus on these two
key players in regulating the epigenetic machinery and will
further address down-stream effects of SIRT1 (Type III
HDAC) down-regulation [6–8].
Recent studies have indicated that bioactive dietary com-
ponents are strong epigenetic modulators that appear to
play a part in prevention of breast cancer [8–10]. A grow-
ing group of studies has indicated that nutritional factors
play an important role in many human diseases and have
been identified and evaluated for their activities against
cancer [11, 12]. One such food source is berries, which
are rich sources of a wide variety of antioxidant phyto-
chemicals such as stilbenes. Stilbenes are natural phenolic
compounds, consisting of resveratrol and pterostilbene.
Resveratrol (3, 4′, 5 trihydroxystilbene) is a natural phyto-
alexin, synthesized by plants such as grapevines, berries
and peanuts in response to an injury [12].
Resveratrol is also enriched in the skin of red grapes,
mulberries, peanuts and pines. The biological role of resver-
atrol is to protect plants against fungal infections (phyto-
alexin), especially against infection with Botrytis cinerea.
Pterostilbene (3,5-dimethoxy-4-hydroxystilbene), found in
blueberries and grapes, is also used as a part of Ayurvedic
medicine for centuries. Chemically, pterostilbene is a di-
methyl ether derivative of resveratrol and, like resveratrol, it
is a phytoalexin.
Both of these key polyphenols have been speculated to
mimic caloric restriction at the molecular level [12] and
are proposed to affect DNA methyltransferase (DNMT)
enzyme activity [13, 14]. However, for the first time we
are reporting the combinatorial effects of these two com-
pounds on inhibiting the activity of SIRT1, a type III his-
tone deacetylase (HDAC). HDACs play a major role in
various cellular processes by preventing chromatin acces-
sibility [11]. Recent studies have shown the importance of
HDAC inhibition and its possible implication in cancer
therapy [8, 10, 11, 15].
SIRT1 is a mammalian homologue of the yeast silent
information regulatory Sir2, which requires nicotina-
mide adenine dinucleotide (NAD+) as a cofactor for its
action. It is a class III HDAC, which is responsible for
modifying histones as well as some non-histone pro-
teins through deacetylation and thereby regulating cell
growth, apoptosis, stress response, adaptation to calorie
restriction, metabolism, cellular senescence and tumori-
genesis [16–18]. Recent studies have highlighted a unique
feature of SIRT1 in regulating DNA damage and repair as
well as its role in maintaining telomere length and gen-
omic stability [11, 19, 20]. Moreover, previous studies have
shown that SIRT1 deficiency impairs the formation of
repair foci which can result in DNA damage, thereby pro-
tecting against tumors by inducting apoptosis [21, 22].
Interestingly, epigenetic patterns can be reversed, and epi-
genetic processes have in recent years become candidates
for drug-mediated therapies.
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In addition to the genetic changes caused by DNA
damage, several tumors often contain epigenetically si-
lenced protective genes with aberrant promoter region
CpG island DNA hypermethylation [11]. Errors in
double stranded break (DSB) repair can also cause muta-
tions and chromosome instability that lead to cancer in-
stead of cell death. SIRT1, when localized to the promoter
of a gene, can also induce gene silencing by increasing the
methylation of the promoter region of that gene by possibly
engaging DNMTs to the damage site [21, 23]. Previous
studies have shown involvement of SIRT1 in upregulat-
ing DNMT1 and DNMT3B presence, specifically at the
DNA damage site [23]. Interestingly, SIRT1 has been
found to localize at the promoters of these methylated-
silenced tumor suppressor genes in some cancer cells,
but not to promoters of the same tumor suppressor
genes were they are normally in an active state [24].
In normal cells, SIRT1 has been linked to the role of pro-
tecting cells against potential carcinogenic agents and envir-
onmental stress. Whereas in malignant growth, it provides
a strong stimulus which involves aberrant methylation as
well as deacetylation of the promoter region of various pro-
tective genes and contributes to gene silencing and initi-
ation and/or maintenance of cancer [18, 21, 23]. This could
also be one of the potential mechanisms for overproduction
of the telomerase enzyme, which enables cancer cells to
replicate indefinitely. For the first time, we are reporting a
relationship between SIRT1 and the human telomerase
reverse transcriptase gene (hTERT) in human TNBC
cells, thus opening a new area which requires further in-
vestigation. These findings suggest that DNA damage may
directly contribute to the large number of epigenetically si-
lenced genes in tumors due in part from hypermethylation
[25–27] and histone deacetylation [10, 15] across the dam-
age region [28] . Human telomerase reverse transcriptase
(hTERT) encodes the catalytic subunit of telomerase and is
an epigenetically-regulated gene. hTERT is over-expressed
in more than ~90 % of human cancers but not in normal
somatic cells. In recent years, hTERT has emerged as a
promising target for cancer therapeutics and is an import-
ant marker for the diagnosis of malignancy [10, 29]. We
have found that combinatorial resveratrol and pterostilbene
resulted in down-regulation of hTERT at both the gene and
enzymatic activity level.
The present study was undertaken to evaluate the com-
binatorial effects of resveratrol and pterostilbene treatment
on TNBC cells. Understanding how these two dietary com-
pounds work may provide important clinical implications
for disease prevention and therapy, further aiding in the de-
velopment of drugs that provide some of the health benefits
of this dietary regimen. The goal of this study was to deter-
mine an optimal bioactive dietary compound combination
regimen, which in turn may enhance future in vivo ana-
lyses and elucidate the translational chemopreventive
potential of targeting epigenetic modulators involved in
TNBC genesis.
Results
Combinatorial resveratrol and pterostilbene can
synergistically inhibit the viability of TNBC cells with no
significant effects on control MCF10A breast epithelial cells
To determine the most effective concentration of these
two dietary compounds on TNBC cells, MTT assays were
performed. As shown in Fig. 1a and b, both the HCC1806
and MDA-MB-157 breast cancer cell lines showed time-
and dose-dependency, with the most effective concentra-
tion of resveratrol at 15 μM and pterostilbene at 5 μM
after 72 h treatments in comparison to individual treat-
ments and DMSO control. The above combination did
not show any significant effects on MCF10A control cells
after 72 h of treatment as depicted in Fig. 1c. Furthermore,
the addition of 15 μM of resveratrol and 5 μM of pterostil-
bene exhibited highly significant inhibitory effects when
compared with single doses and combinatorial treatments
at 24 h. This inhibitory effect of 15 μM of resveratrol and
5 μM of pterostilbene in combination was found to be
synergistic (Combination index <1) in their mode of ac-
tion in both TNBC cell lines as determined by CompuSyn
software [30]. The morphology of human breast cancer
cells treated with resveratrol and pterostilbene was also
changed as shown in Fig. 2a and b. Combinatorial treat-
ments resulted in more spherical cellular morphology with
increased floating cells, indicating both cell death and
inhibited cellular proliferation in these two breast can-
cer cell types. The equivalent doses of both resveratrol
and pterostilbene alone as well as in combination were
found to have no significant effects on control MCF10A
breast cells (Fig. 2c) after 72 h of treatment, indicating
safety at these levels. In order to investigate the long term
effects of this combination on tested cell lines, colony form-
ing assays were performed. The results are highlighted in
Table 1 and the observations appear in Table 1 legend.
Resveratrol and pterostilbene combination induces
apoptosis in breast cancer cells with no significant
apoptotic effects on MCF10A control breast cells
A decrease in cell viability can be achieved by inhibiting cell
cycle progression and/or by inducing cellular apoptosis. In-
duction of apoptosis is one of the major mechanisms by
which a chemotherapeutic agent can be effective [8, 31]. To
further determine the effectiveness of this combination
regimen, we studied the apoptotic potential of resvera-
trol and pterostilbene on two different breast cancer
cell lines. Figure 3a shows the effect of these two com-
pounds on HCC1806 breast cancer cells. With 15 μM
resveratrol and combinatorial treatment, there was a signifi-
cant increase in apoptotic cells in relationship to DMSO
(vehicle control). In addition, combinatorial treatment was
Kala et al. BMC Cancer  (2015) 15:672 Page 3 of 18
also found to be highly significant with either 15 μM resver-
atrol or 15 μM pterostilbene alone. Figure 3b shows
the effect of these two compounds on MDA-MB-157
breast cancer cells. Apoptosis was observed with both
pterostilbene-treated (5 μM) and the combination set,
which was highly significant in comparison to DMSO.
In contrast to the above TNBC cell lines, there was no sig-
nificant apoptosis observed in the MCF10A control breast
Fig. 1 Time- and dose-dependency of resveratrol (Res) and pterostilbene (Ptero) in inhibiting cellular viability. Different concentrations of resveratrol and
pterostilbene were used singly as well as in combination for 24 h (one day) and 72 h (three day) to determine time- and dose- dependent inhibition in
both the breast cancer cell lines. With 72 h treatments, the combinatorial resveratrol and pterostilbene showed a highly significant inhibition in comparison
to the DMSO control, both single and combinatorial treatments at 24 h and single doses at 72 h. After determining the significance, the combination index
(CI) of these two drugs at 72 h was determined using CompuSyn software. Resveratrol at 15 μM and pterostilbene at 5 μM in combination were found to
exhibit synergism (indicated by triangle) with the lowest CI value among all of the combinations used (See Additional files 1 and 2). a Effects of resveratrol
and pterostilbene single and combinatorial treatments on HCC1806 breast cancer cells. With 72 h of combinatorial treatment, these cells incurred a highly
significant inhibition in comparison to the DMSO control and different treatments at 24 h. b Effects of resveratrol and pterostilbene single and combination
treatments on MDA-MB-157 breast cancer cells. This cell line also showed a highly significant inhibition at 72 h (three days) treatments in comparison to
the DMSO and different treatments at 24 h. Both the cancer cell lines showed time- and dose-dependent inhibition and combinatorial 15 μM of resveratrol
and 5 μM of pterostilbene was also found to exhibit synergism as determined by CI values. c Different concentrations of resveratrol and pterostilbene were
used to treat MCF10A control cell breast cells for 72 h to determine toxicity. No significant inhibition was observed in comparison to vehicle control. Values
are representative of three independent experiments and are shown relative to control ± SE; *P <0.05, **P <0.01. Res, resveratrol; Ptero, pterostilbene
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cells (Fig. 3c) after 72 h of treatment with the respective
compounds. These observations suggest that resveratrol at
15 μM and pterostilbene at 5 μM can induce cellular
apoptosis without any effects on MCF10A control breast
cells, thus suggesting their potential efficacy for future
chemotherapy.
Combined resveratrol and pterostilbene arrest HCC1806
cells predominantly in G2/M phase and MDA-MB-157 cells
in both G2/M and S phase
Cell cycle progression analysis revealed a predominant ar-
rest of HCC1806 cells in G2/M phase (Fig. 4a), which could
account for the significant level of apoptosis in these breast
Fig. 2 Morphology of breast cancer cell after 72 h of treatment in 6-well plates. a Effects of resveratrol and pterostilbene on HCC1806 breast cancer cells.
With combinatorial treatments, cells showed changes in morphology with increased amorphous floating bodies indicating cell death (indicated by arrow).
b Effects of resveratrol and pterostilbene on MDA-MB-157 cells. With combinatorial treatment, cells showed a decrease in cellular proliferation and became
amorphous (indicated by chevron). c No change in cellular morphology was observed with single or combinatorial treatments of compounds on MCF10A
breast epithelial control cells. Images were taken at 100X magnification
Table 1 Colony forming potential in TNBCs and MCF10A control cells
Treatments (10 days) Cells plated Colony counted Plating efficiency (%) Survival fraction (%)
M DA-MB-15 7
DMSO 500 490 98 100.00
Res 15 500 399 79.8 81.43
Ptero 5 500 417 83.4 85.10
Combination 500 220 44 44.90
Treatments Cells plated Colony Plating Survival fraction
(14 days) counted efficiency
MCF10A
DMSO 500 165 32.96 100
Res 15 450 136 30.33 92.03
Ptero 5 500 175 35.06 106.3
Combination 480 145 30.13 91.44
After staining the tissue culture dishes (20 mm), colonies were counted using a colony counter. Large colonies consisting of 50 or more cells were counted. MDA-MB-157
breast cancer cells displayed a reduction in colony forming potential after different treatments as determined by survival fraction (%). This reduction was more effective
in combination treatments when compared with single doses of resveratrol (15 μM) and pterostilbene (5 μM) alone. Interestingly, MCF10A control cells did not display a
significant change in the colony forming potential when compared within the treatment groups and the DMSO treated group. These observations further provide the
effectiveness of this combinatorial regimen in inhibiting breast cancer cells growth. However, HCC1806 breast cancer cells did not form any successful colonies in any of
the groups (data not shown). Values are representative of three independent experiments
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cancer cell lines upon combination treatment. Figure 4b
depicts a shift of cells from G2/M phase with 15 μM resver-
atrol treatment to S phase with 5 μM pterostilbene and
combination treatments.
Combinatorial treatment inhibits SIRT1 in breast cancer cells
To further understand the mechanism of action of res-
veratrol and pterostilbene, we investigated the effects of
these compounds on SIRT1. This important enzyme is
a class III histone deacetylase (HDAC), which is respon-
sible for modifying histones as well as some non-histone
proteins through deacetylation and thereby regulating cell
growth, apoptosis, stress response, adaptation to calorie re-
striction, metabolism, cellular senescence and tumorigen-
esis. Figure 5 demonstrates the effects of resveratrol and
pterostilbene on SIRT1 in HCC1806 and MDA-MB-157
breast cancer cells, respectively. Figure 5a and d show
effects at the mRNA level and Fig. 5b and e show the ef-
fects of combination treatment on enzyme activity, repre-
sented as a percentage relative to DMSO. In both the cell
lines, with an optimal combination of 15 μM resveratrol
and 5 μM pterostilbene, there was a significant inhibition
of SIRT1 at both the gene and enzyme level in comparison
to single-compound administration and DMSO treat-
ments. Figure 5c and f show the western blot analysis
of SIRT1 in HCC1806 and MDA-MB-157 breast cancer
cells and further confirm these inhibitory effects. Inter-
estingly, there was no significant change in the relative
percent activity of SIRT1 in MCF10A control breast
cells (Fig. 5g).
Resveratrol and pterostilbene alter DNA damage
response (DDR) in breast cancer cell lines
Research has shown that chromatin structure plays a crit-
ical role in DDR following DNA damage. Phospho-H2AX
is a marker for the DNA damage and repair mechanism.
Various cancers are marked by unchecked cell cycles which
usually results in increased rates of DNA damage and mu-
tation, causing an increased expression of γ-H2AX [32]. In
recent years, SIRT1 has been reported to regulate the DNA
Fig. 3 Combinatorial resveratrol and pterostilbene induces apoptosis in breast cancer cells. a HCC1806 cells undergo tremendous apoptosis
after 72 h of treatment with resveratrol at 15 μM and combinational treatments at 15 μM resveratrol and 5 μM pterostilbene. Percent
apoptosis in combinatorial treatment in HCC1806 cells was significantly elevated in comparison to DMSO (vehicle control) and individual
treatments. b MDA-MB-157 cells underwent apoptosis with 5 μM pterostilbene and combinational treatment by 72 h. Both of the cell types
were found to be highly significant in change in percent apoptosis in comparison to DMSO (vehicle control). c MCF10A cells did not show
any significant change in apoptosis after 72 h of treatment with any of the tested compounds. Values are representative of three independent
experiments and are shown as percent of control ± SE; *P <0.05, **P <0.01
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damage and repair mechanism along with H2AX [21]. In
the present study, the combination treatment of 15 μM res-
veratrol and 5 μM pterostilbene resulted in apoptosis in
both the breast cancer cell lines. To further understand the
mechanism of action of these two compounds, phopho-
H2AX levels were analyzed using western bolting (Fig. 6)
and immunofluorescence (IF) microscopy (Fig. 7). Figure 6a
reveals a highly significant (P <0.01) decrease in γ-H2AX
in HCC1806 cells subjected to combinatorial treatment.
MDA-MB-157 cells also displayed a decrease in γ-H2AX
level with both 15 μM resveratrol and combination treat-
ment (Fig. 6b). Effects of compounds were also analyzed in
MCF10A control cells (Fig. 6c). Importantly, there was no
change in the expression of γ-H2AX as analyzed by
western blot in the control cells. To further strengthen
these findings and determine the mechanism of action
of these two compounds, SIRT1 knockdown was performed
and its effects observed on γ-H2AX in HCC1806 cells.
Figure 6d shows a decrease in the expression of γ-H2AX,
further providing a link between SIRT1 and γ-H2AX. In
order to confirm this decrease in γ-H2AX levels, IF micros-
copy was performed in HCC1806 breast cancer cells (Fig. 7).
SIRT1 knockdown was also performed to establish a con-
necting link between SIRT1 down-regulation and genomic
instability by targeting γ-H2AX protein. DAPI (blue) was
used to stain cell nuclei and Alexa Fluor®488 GFP (green)
was used to stain γ-H2AX protein. It was interesting to
observe a decrease in γ-H2AX protein in combination
treatments as well as in SIRT1 knockdown set in HCC1806
breast cancer cells as depicted in Fig. 7. These observations
were found to be consistent with our previous western blot
findings (Fig. 6).
Effects of the combination regimen on DNA
methyltransferase enzymes (DNMTs) in HCC1806 breast
cancer cells and MCF10A control cells
To further explore the mechanism for our observations, we
next focused on HCC1806 cells since few differences were
observed between the HCC1806 and MDA-MB-157 cell
types in the prior studies. To help elucidate the mechanism
of action of these two polyphenols, their effects were
observed on DNMTs expression. Figure 8a shows the
effect of these compounds on the relative mRNA expres-
sion of DNMT1, DNMT3A and DNMT3B in HCC1806
breast cancer cells. With the combination treatment, all
the DNMTs underwent a significant down-regulation at
the mRNA level. Further, the effects of these polyphenols
were observed on overall DNMT enzyme activity. Figure 8b
shows a significant decrease in overall enzyme activity with
resveratrol (15 μM), pterostilbene (5 μM) and combination
treatment. To further strengthen this study, overall DNMT
enzyme activity was analyzed in MCF10A control cells.
Figure 9 shows no significant change in the overall enzyme
activity within the treatment groups.
Resveratrol and pterostilbene inhibits hTERT expression in
HCC1806 cells
To explore the mechanistic effects of resveratrol and pter-
ostilbene, the expression level of human telomerase reverse
transcriptase (hTERT) was analyzed. The hTERT gene has
Fig. 4 Resveratrol and pterostilbene arrest cells in G2/M and S phase of cell cycle. a HCC1806 breast cancer cells were arrested in G2/M phase
with combinatorial treatment after 72 h. b MDA-MB-157 breast cancer cells were arrested in G2/M phase with 15 μM resveratrol and in S phase
with combination treatment after 72 h. Data shown are representative of three different experiments
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previously been noted to be under epigenetic regulation
[10, 31]. As shown in Fig. 10a, relative hTERT mRNA
level is down-regulated after resveratrol and pterostilbene
combination treatment. Furthermore, the telomerase
activity assay also indicated an overall time-dependent
decrease as analyzed by telomeric repeat amplification
protocol (TRAP) assay and depicted in Fig. 10c.
SIRT1 knockdown resulted in hTERT down-regulation in
HCC1806 breast cancer cells
To further explore the mechanism of action of these
two dietary polyphenols and to determine the role of
SIRT1 in telomerase expression, knockdown of SIRT1
was performed. As shown in Figs. 10b and 6d, a
successful SIRT1 knockdown was performed as depicted
by RT-PCR and western blot analysis. Figure 10b shows a
decrease in hTERT mRNA level in the SIRT1 knock-
down set in comparison to the control. To further
confirm the cross-talk between SIRT1 and hTERT,
TRAP analysis was performed as shown in Fig. 10c.
There was a significant decrease in telomerase activity
in SIRT1 knockdown sample, suggesting an existing
cross-talk between these two key cancer-associated
proteins.
Fig. 5 Combinatorial resveratrol and pterostilbene inhibited SIRT1 in TNBCs with no effects in breast control cells. a and d Relative real-time SIRT1
mRNA expression after 72 h of treatments in HCC1806 cells and MDA-MB-157 breast cancer cell lines, respectively. With combination treatment,
there was a significant down-regulation of SIRT1 mRNA. GAPDH was used as the internal control. b and e Percent SIRT1 enzyme activity relative
to DMSO control after 72 h of treatment with compounds alone as well as in combination in HCC1806 and MDA-MB-157 cells, respectively, using
20 μg of nuclear extract. With combinatorial treatment, a significant down-regulation in SIRT1 enzyme activity occurred which was found to be
consistent with real-time data. c and f SIRT1 protein western blot after 72 h of treatment with compounds alone as well as in combination in
HCC1806 and MDA-MB-157 cells, respectively. β-Actin was used as an internal control. With combination treatment, there was a decrease in SIRT1
protein as evident by western blot which is consistent with real-time and activity data. g No significant change observed in SIRT1 enzyme activity
in MCF10A breast control cells after 72 h of treatment with compounds alone or in combination. Values are representative of three independent
experiments and are shown as percent of control ± SE; *P <0.05, **P <0.01
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Effects of compounds on telomerase enzyme activity in
MCF10A control cells
In order to further understand the effectiveness and fi-
delity of the compounds used in this study, we analyzed
the expression of telomerase in MCF10A control cells
using TRAP activity kit. From the previous results in
this study which highlighted a time-dependency of the
telomerase enzyme, MCF10A cells were treated with
the compounds for 5 days and then analyzed. Figure 11
showed a slight increase in the telomerase enzyme
activity at 15 μM resveratrol and combination treat-
ments. However, this increase in the enzyme activity is
insignificant when compared with a positive control, as
shown in Fig. 11.
Discussion
Most compounds used in chemotherapy are synthetic or
analogs of compounds that are present in dietary food
sources. The application of these compounds in treat-
ment often requires high dosage and prolonged exposure
for therapy-related effectiveness. Unfortunately, such treat-
ments often result in problems such as non-specific tissue-
cell cytotoxic effects and multi-drug resistance tumors. To
avoid these issues, it is imperative that the chemicals used
in the treatment should be safe, easily available and
cost-effective. Most dietary epigenetic phytochemicals
meet these criteria and can be administered as dietary
supplements, thereby offering promising new options
for the development of more effective chemopreventive
Fig. 6 Resveratrol and pterostilbene effects on γ-H2AX expression. a Densitometry analysis and western blot of γ-H2AX protein after 72 h of treatment
with compounds alone as well as in combination in HCC1806 breast cancer cells. β-Actin was used as an internal control. With combination, there was
significant decrease in γ-H2AX protein expression. Values are representative of three independent experiments ± SE; *P <0.05, **P <0.01. b Densitometry
analysis and western blot of γ-H2AX protein after 72 h of treatment with compounds alone as well as in combination in MDA-MB-157 breast cancer cells.
β-Actin was used as an internal control. With combination, (P <0.01) as well as 15 μM resveratrol (P <0.05) treatment, there was a decrease in
γ-H2AX protein expression, and combination treatment was found to be highly significant (P <0.01) when compared with all the treatment
groups. Values are representative of three independent experiments ± SE; *P <0.05, **P <0.01. c Effect of compounds alone as well as in combination
on g-H2AX protein in MCF10A control cells after 72 h of treatment. β-Actin was used as an internal control. No significant change in g-H2AX protein
expression was observed with the following treatments. d SIRT1 knockdown western blot in HCC1806 cells using 3 μl of transfecting agent and 30 nM
of SIRT1 siRNA. With the knockdown, there was a decrease in γ-H2AX protein expression. Scrambled control did not show any effects. β-Actin was used
as an internal control. Data shown are representative of three separate experiments
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Fig. 7 Effects of combination and SIRT1 knockdown on γ-H2AX protein expression in HCC1806 breast cancer cell line as analyzed by immunofluorescence
microscopy. DAPI was used to stain cell nuclei, shown in blue color. Alexa Fluor®488 (GFP) shown in green was used to stain the target protein. a Shows
the expression of γ-H2AX protein in green with live cells stained in blue after 72 h of DMSO treatment in HCC1806 breast cancer cells. b and c The effect
of 15 μM resveratrol and 5μM pterostilbene treatments after 72 h are demonstrated. Images show no change in the intensity of blue and
green color between the two sets as marked by the red arrows. d Effects of combination after 72 h of treatment depict a significant change
in the intensity of green color (γ-H2AX protein) in comparison to the blue color stained nuclei. e Effect of SIRT1 knockdown in HCC1806 breast
cancer cells. This resulted in decreased γ-H2AX protein expression (green color) as marked by red arrows
Fig. 8 Combination treatments altered epigenetic enzyme expression and their activity in HCC1806 breast cancer cells. a Resveratrol and pterostilbene
after 72 h of treatment affected DNMTs (DNMT1, DNMT3A, DNMT3B) mRNA expression. With the combination of resveratrol and pterostilbene all three
DNMTs were significantly down-regulated. Resveratrol at 15 μM also resulted in a decrease in DNMT3B mRNA expression after 72 h. GAPDH was used as
an internal control. b Overall DNMT enzyme activity analysis, using 20 μg of nuclear extract. After 72 h, the entire treated group resulted in a significant
down-regulation of enzyme activity in comparison to DMSO control. There was no significant difference in overall enzyme activity within the treatment
group itself. Values are representative of three independent experiments and represented as percent of control ± SE; *P <0.05, **P <0.01
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Fig. 9 Combination treatments did not alter epigenetic enzyme expression and their activity in MCF10A control cells. Overall DNMT enzyme activity
analysis, using 20 μg of nuclear extract. After 72 h, there was no significant change in the enzyme activity in comparison to DMSO control in MCF10A
control cells further highlighting the effectiveness of this combination regimen. Values are representative of three independent experiments and
represented as percent of control ± SE; *P <0.05, **P <0.01
Fig. 10 Effects of combination and SIRT1 knockdown, on hTERT expression in HCC1806 breast cancer cells. a Combination (Res/Ptero) treatment after 72 h
rendered a significant down-regulation of hTERT mRNA levels as shown by real-time PCR. GAPDH was used as an internal control. Values are representative
of three independent experiments ± SE; *P <0.05, **P <0.01. b SIRT1 knockdown (SIRT1 KD) was performed and its effects on hTERT mRNA were analyzed
using real-time PCR. After 72 h of knockdown, there was a significant down-regulation of both SIRT1 and hTERT mRNAs. No significant effects
were observed with scrambled siRNA. GAPDH was used as an internal control. Values are representative of three independent experiments ± SE; *P <0.05,
**P <0.01. c Telomerase enzyme activity was analyzed using TRAP assays in the HCC1806-treated and knockdown set. At the fourth and fifth days
of treatment, there was a significant down-regulation of telomerase activity with the combination of resveratrol and pterostilbene. SIRT1 knockdown
also resulted in significant down-regulation of telomerase enzyme activity at fifth day. Values are representative of three independent experiments and
are shown as percent of control ± SE; *P <0.05, **P <0.01
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and chemotherapeutic strategies [10]. Resveratrol and
pterostilbene are two phytoalexins produced by plants
in response to an infection. Ideally, they are the plants’
own defense system. Once the mechanistic pathways of
phytochemicals are determined, modification of these com-
pounds to increase their stability without compromising
their therapeutic efficacy can be achieved [9]. The combin-
ation of two biomolecules can synergistically or additively
improve the therapeutic impact on tumors at lower doses
than when used alone.
In the present study, resveratrol or pterostilbene single
treatment, as well as combination treatment, was admin-
istered to breast cancer and control breast cells. The
concentrations we used in this study model are close to
a normal physiologically achievable range [33, 34]. De-
pending on the expression of the receptors, breast can-
cers can be classified into various groups. Breast cancers
which are positive for estrogen receptor (ER), progester-
one receptor (PR), and human epidermal growth factor
receptor 2 (HER2) represent discrete biological entities
with distinct clinical profiles and are often associated with
better prognosis and can be treated with hormone therapy.
In contrast, women with triple-negative breast cancers
[TNBC (i.e., ER-, PR-, and HER2-)] are typically associ-
ated with less favorable prognosis [35, 36] and account
for about 10–20 % of breast cancers. Breast cancers
which are ER-, PR- and HER2-negative cannot be success-
fully treated with hormonal therapies or medications that
work by blocking the receptor and are often fatal. We
undertook this study in part to address this important chal-
lenge. TNBC used in this study were MDA-MB-157 and
HCC1806 cells. MCF10A breast non-tumorigenic epithelial
cells were used as a control cell line to determine the tox-
icity and efficacy of our combinatorial dietary regimen.
Cell viability analysis was performed for 24 h and 72 h
using various concentrations of resveratrol and pterostil-
bene to determine time- as well as dose-dependency in
all breast cancer cell lines. The combination effect was
also analyzed on breast control (MCF10A) cells for 72 h
to detect any evidence of toxicity. Resveratrol at 15 μM
with pterostilbene at 5 μM after 72 h was found to be
the most effective combination and was highly signifi-
cant when compared with DMSO and 24 h of combin-
ation treatments. This combination in both the cell lines
was found to possess synergism when compared with
different combination doses after 72 h of treatments.
Combination index (CI) values at 72 h of treatment for
HCC1806 and MDA-MB-157 breast cancer cells were
found to be the lowest with respect to other CI values
(See Additional files 1 and 2). The CompuSyn software
used to calculate synergy generates different values of com-
bination index where CI <1, synergism; CI = 1, additive ef-
fects; CI >1, antagonism, and have been employed for drug
combination and general dose effect analysis in various
studies [30, 37]. Our analysis using CompuSyn software
indicated that combination treatments lower than 15 μM
resveratrol and 5 μM pterostilbene at 72 h showed less
effectiveness and qualitatively displayed a degree of antag-
onism, addictiveness and/or moderate synergism in both
types of breast cancer cells (see Additional files 1 and 2).
Collectively, both resveratrol and pterostilbene were found
to exhibit dose- and time-dependent inhibitory effects on
TNBC cells. Interestingly, the same concentration was used
to treat breast control MCF10A cells and did not result in
Fig. 11 Effects of compounds on telomerase enzyme in MCF10A breast control cells. Telomerase enzyme activity was analyzed using TRAP assay
in the MCF10A control cells. After five days of treatment, there was a significant up-regulation in telomerase activity in 15 μM resveratrol (P <0.01)
treated group and combination treatment (P <0.05) when compared with the DMSO treatment. Pterostilbene (5 μM) did not show any significant
change in the telomerase enzyme activity. A positive control (PC) was used in the experimental design in order to understand this up-regulation in the
treated group. The difference in the enzyme activity between the treatment groups and PC was highly significant (P <0.01). Moreover, the PC displayed
around 200 fold more active telomerase enzyme as compared to the experimental values. Values are representative of three independent experiments
and are shown as percent of control ± SE; *P <0.05, **P <0.01
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any significant inhibition. To further confirm the effects
over a long term, colony forming assays were performed in
the tested cell lines (Table 1). Depending on the growth rate
and colony forming potential of the cells, MDA-MB-157
breast cancer cells were analyzed for 10 days and MCF10A
control cells were analyzed for 14 days. The combination of
two polyphenols displayed a decreased in the colony form-
ing potential of MDA-MB-157 cells with no significant de-
crease in MCF10A control cell. Ironically, HCC1806 breast
cancer cells did not form successful colonies (≥50 cells).
Cells were plated at an increased seeding density from 200
cells/plate to 1000 cells/plate from 7 days to 15 days, none
of them formed successful colonies (data not shown). One
explanation for this uncertainly could be due to critical
density phenomenon in which cells won’t grow if they are
too widely dissociated and makes too few contacts with
other cells. The goal of this study was to determine the
effects of resveratrol and pterostilbene combination treat-
ment on both of these TNBC cell lines and to reveal the
potential mechanism responsible for the effect. Our results
indicated for the first time that resveratrol and pterostilbene
can synergistically inhibit cellular viability in combination
and can further impact cellular proliferation through cell
cycle arrest and apoptosis induction in TNBC cells. Inter-
estingly, the combination treatment in HCC1806 cells re-
sulted in a tremendous apoptosis induction in comparison
to DMSO and individual treatments. Moreover, treatment
of MDA-MB-157 cells also resulted in apoptosis although
the rate of apoptosis in comparison to HCC1806 cells was
less but nevertheless significant.
Progress through each phase of the cell cycle is regulated
carefully to avoid proliferation. Cells can be arrested in G1,
S and G2/M phases to prevent any replicative errors. Can-
cer cells are characterized by unchecked cell cycles, often
resulting in uncontrolled replicative errors and DNA dam-
age. Previous studies have shown the role of p53 in arrest-
ing cells in G1 phase but not in S and/or G2/M phases
[31]. Our experiments with resveratrol and pterostilbene
combination treatment in HCC1806 and MDA-MB-157
cells resulted in predominant G2/M phase and S phase ar-
rest, respectively. These observations have been found to be
consistent with previous studies involving defective p53 sta-
tus in various cancer cell lines [8, 31]. Resveratrol and pter-
ostilbene combination at close to physiologically achievable
concentration are shown in this investigation to inhibit can-
cer cell growth by inhibiting cell cycle progression and by
the induction of apoptosis in these TNBC cells, with no sig-
nificant effects in MCF10A control cells.
SIRT1, a class III histone deacetylase (HDAC) has been
linked in normal cells to a role in protecting cells against
potential carcinogenic agents and environmental stress.
Whereas, in malignant growth it provides a strong stimu-
lus, involving aberrant methylation and deacetylation of
the promoter region of various genes and contributes to
gene silencing, resulting in initiation and/or maintenance
of cancer [17–19, 25]. SIRT1 knockdown also results in
cell cycle arrest and apoptosis induction. SIRT1 is one of
the key epigenetic-modifying enzymes which, by itself or
in complex, implements various cellular events such as
DNA damage response (DDR), regulating stress, stabiliz-
ing the damage DNA along with γ-H2AX and DNMT’s
and stabilizing eroded telomeres [11, 18, 21, 28, 38, 39].
For the first time, we have reported a significant down-
regulation of SIRT1 with this combinatorial dietary
approach. This down-regulation was confirmed at the
transcriptional and translational as well as enzymatic
levels. There was no significant change observed at the
enzyme activity in MCF10A breast epithelial control
cells, further suggesting the effectiveness and utility of
this combinatorial approach.
DNA double-strand breaks are serious lesions which can
lead to genomic instability and to cancer. A key marker and
a way to monitor the DNA damage and repair mechanism
is Phospho-H2AX [38]. H2AX is a member of the histone
H2A family, one of the five histones that form chromatin
along with eukaryotic DNA. SIRT1, along with γH2AX and
ataxia telangiectasia mutated (ATM), is recruited to the
DNA damage site and participates in the formation of re-
pair foci [18, 21] and plays a role in stabilizing repair foci
containing DNA repair factors. This mark is maintained at
the break site until the break is repaired [18, 21]. Consistent
with previous studies, cell lines with defective p53 show a
longer persistence of γH2AX, as an indicator of stress [32].
Resveratrol and pterostilbene in combination showed a sig-
nificant down-regulation of γH2AX (72 h) in both tested
cancer cell lines with no effects on MCF10A control cells,
further demonstrating the effectiveness of this dietary regi-
men in affecting DDR. This could also account for the in-
creased apoptosis in both the cancer cell lines with this
combination treatment. This γH2AX down-regulation in
HCC1806 breast cancer cells was also confirmed using IF
microscopy and interestingly was found to be consistent
with our western blot data.
Recent studies demonstrated the recruitment of DNA
methyltransferases (DNMTs) enzymes along with SIRT1
to the site of DNA damage as a part of the repair mech-
anism, which might be defective in cancer cells, resulting
in hypermethylation of CpG-island promoters across the
double stranded break [17, 23]. DNA methyltransferases
and histone modifying enzymes are no longer considered
independent epigenetic regulators, but are supposed to
work in tandem or in cohesion to alter the epigenome.
HDACs and DNMTs have been shown to assist with the
DNA damage response by recruiting various other repair
proteins to the site of damage. HDAC inhibitors such as
butyrate and trichostatin A (TSA) have been shown to
affect the repair machinery [18]. Double-stranded breaks
can cause the development of cancer and also result in
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the induction of a hypermethylated state with the aid of
silencing factor, SIRT1. Thus, in cancer cells we may ob-
serve increased expression of SIRT1, DNMTs and γ-H2AX
proteins, as they are the key markers for genomic stress,
DNA damage and repair foci formation [18, 23, 32, 38].
These two dietary polyphenols when administered (72 h) in
HCC1806 breast cancer cells resulted in down-regulation
of DNMT1, 3A and 3B at the gene level as well as at the en-
zymatic activity level in HCC1806 breast cancer cells. Inter-
estingly, there was no significant change in overall DNMT
enzyme activity in MCF10A control cells after 72 h of treat-
ment. Thus, the observed molecular and cellular effects in
this investigation could be due to a combined effect of this
dietary regimen on SIRT1 and DNMT enzymes levels.
With every cell division eroded-critically short telomeres
reveal double-strand breaks resulting in cellular senescence
in normal mammalian cells [40], whereas under abnormal
circumstances, they transform into cancer cells in lieu of
senescence and/or apoptosis. The catalytic subunit of the
enzyme telomerase (hTERT) is highly expressed in ~90 %
of human cancers [10, 31]. Previous studies with normal
human umbilical cord fibroblasts and stem cells have re-
ported the role of SIRT1 in increasing the transcription of
hTERT either directly by the involvement of FOXO3a and/
or indirectly by affecting c-MYC [20, 39]. For the first time,
we have reported down-regulation of hTERT with the use
of resveratrol and pterostilbene in combination at close to
physiological relevant doses in HCC1806 breast cancer
cells. This down-regulation was evidenced by both real-
time PCR and telomerase activity (TRAP) assay. Consistent
with the previous studies, a time-dependent inhibition of
telomerase enzyme was observed because of the stable
half-life of telomerase enzyme [41, 42]. To further under-
stand the mechanism of hTERT down-regulation, SIRT1
knockdown was performed in HCC1806 breast cancer
cells. It was discovered that SIRT1 knockdown in human
breast cancer cells resulted in a decrease in hTERT mRNA
expression at the third day and enzyme activity at the fifth
day of treatment as evidenced by RT-PCR and TRAP activ-
ity, respectively. One explanation for this hTERT down-
regulation, which could account for growth inhibition in
the breast cancer cells, could be due to a decrease in the
downstream target of SIRT1, FOXO3a and c-MYC, which
has been shown to increase hTERT expression in a SIRT1-
dependent manner [20, 39]. Alternatively, many proteins
involved in DDR also play a key role in telomere mainten-
ance. One such protein is SIRT1, along with γ-H2AX and
DNMTs, which are documented to maintain and stabilize
the repair site and are significantly down-regulated in the
present study [11, 28, 39]. Overall the effect of this dietary
regimen was also analyzed on MCF10A control cells in
order to determine the effectiveness of this approach. At
the fifth day of the treatment there was a slight increase in
telomerase activity in resveratrol (15 μM) and combination
treatments when compared with the DMSO set, but this
increase in activity was significantly below the positive con-
trol TRAP readings.
In the future, this dietary regimen may be used to
provide a safe and effective treatment for TNBCs. It is
documented that targeting γ-H2AX may also enhance
the cytotoxic effects of irradiation therapy (IR), while
circumventing adverse effects on unirradiated cells [43].
This down-regulation is also documented to sensitize cells
to DNA damaging agent such as cisplatin [44]. Hence,
combining DNA damaging agents (such as IR and cis-
platin) with the current dietary regimen might provide
a better treatment option. SIRT1, a key silencing factor
known to be involved in a variety of cellular processes
including DDR response and γ-H2AX expression, is
shown in our study to participate in regulating hTERT
expression, thereby opening future investigation which
includes promoter-specific analysis of hTERT gene.
Conclusion
Our results indicate that combinatorial resveratrol and
pterostilbene at close to physiological-relevant concen-
tration, synergistically and significantly inhibit prolifera-
tion of both MDA-MB-157 and HCC1806 breast cancer
cells with no significant effects on control MCF10A breast
epithelial cells, providing effectiveness and safety of this
dietary regimen. This combination treatment resulted in
predominantly G2/M and S phase cell cycle arrest along
with apoptosis induction in these two TNBC cell lines. For
the first time, this dietary regimen demonstrated down-
regulation of type III HDAC, SIRT1, and impacted the
DNA damage and response mechanism, further reflected
by down-regulation of γ-H2AX and hTERT expression and
increased apoptosis. HDAC inhibition appears to facilitate
cancer cell death and holds a potential promise in the de-
velopment of future cancer therapies. Plant-based dietary
polyphenols used in this study targeted DNMT’s activity,
which might further affect some methylation patterns
downstream and is subject for future studies. Results
obtained so far indicate the unique role of these two
polyphenols in affecting breast cancer and opens new
possibilities and pathways to target in cancer. This com-
bination can also be used to study the effects on miRNA,
which hold a great potential in regulating epigenetics
events in the cells.
Methods
Cell lines
Breast cancer cell lines MDA-MB-157, HCC1806 and
MCF10A were obtained from ATCC. MDA-MB-157 and
HCC1806 are both triple-negative (ER-, PR-, HER2-) and
p53 null. Clinically, MDA-MB-157 cells were initially ob-
tained from a 44 year-old black female with medullary car-
cinoma of breast and HCC1806 cells were obtained from
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60 year-old black female with acantholytic squamous car-
cinoma of the breast. This allowed us to target two broad
age groups of aggressive breast cancers with triple-negative
status. MCF10A is an immortalized, non-tumorigenic epi-
thelial cell line used as a control in this study as commonly
done [10]. MDA-MB-157 cells were grown in DMEM
media (Mediatech Inc, Manassas, VA) and HCC1806
cells were grown in RPMI 1640 media (Mediatech Inc,
Manassas, VA) supplemented with 10 % fetal bovine serum
(Atlanta Biologicals, GA) and 1 % penicillin/streptomycin
(Mediatech). MCF10A cells were grown in F12-DMEM
media supplemented with the necessary antibiotics and
growth supplements as required by the ATCC protocol.
The cells were subcultured at 75 % confluence. All of the
cell lines were maintained in an incubator at 5 % CO2 with
a controlled temperature of 37 °C.
Chemicals
Resveratrol (>99 % pure; GC) and pterostilbene (>97 %
pure; HPLC) were purchased from Sigma-Aldrich. The
compounds were prepared in dimethyl sulfoxide (DMSO),
which was obtained from Sigma-Aldrich and stored at a
stock concentration of 50 mM at –20 °C. Cells were treated
with fresh resveratrol (Res) and pterostilbene (Ptero) every
24 h (one day) for up to 72 h (three days) after seeding.
DMSO (1 μL/1 ml) was used as the vehicle control.
MTT analysis
The number of viable cells in each well was estimated by
the uptake of the tetrazolium-salt, 3-(4, 5-dimethylthiazol-
2-yl)-diphenyltetrazoliu bromide (MTT). Approximately
5000 breast cancer cells were plated in 96- well plates and
allowed to attach to the bottom of the plate overnight.
Cells were then treated with increasing doses of res-
veratrol (5, 10, 15 μM) or pterostilbene (5, 10, 15 μM)
or combinatorial resveratrol and pterostilbene (5 + 5,
5 + 10, 5 + 15, 10 + 5, 10 + 10, 10 + 15, 15 + 5, 15 +
10, 15 + 15 μM) for one day and/or three days to de-
termine dose-as well as time-dependency. At the end
of each treatment, cells were incubated with 100 μ1 of
1 μg/ml MTT for 2 h at 37 °C. The converted purple
insoluble formazan, by mitochondrial enzyme, was
further dissolved using 100 μl of DMSO. Readings
were acquired at 595 nm using a microplate reader
(iMark™, Bio-Rad). Relative cell viability was calculated
in comparison to DMSO vehicle control.
Morphological analysis
After determination of the optimal and safe concentrations
of dietary compounds, approximately 8 × 104 cells/2 ml
were plated in 6-well plates. Medium containing freshly
added resveratrol (15 μM), pterostilbene (5 μM) and com-
bination of resveratrol + pterostilbene (15+5 μM) was
added for 72 h. Morphology of cells was observed under a
phase contrast microscope at magnification of 100×. Im-
ages of cells were captured with a Nikon Coolpix P5100
(Nikon, Tokyo, Japan).
Colony forming assay
Cell were plated overnight in 6-well plates and then treated
the next day for up to 24 h. Following treatment, single cell
suspensions were obtained. The number of cells in each
sample were counted carefully using a hemocytometer and
diluted such that appropriate cell numbers are seeded into
tissue culture dishes. Dishes were arranged in an incubator
at 5 % CO2 with a controlled temperature of 37 °C.
The incubation time for colony formation varies from
1 to 3 weeks for different cell lines. After incubation,
colonies were fixed using 100 % ice-cold methanol for
10–15 mins. After fixing, colonies were stained using
0.1 % CV for 10–15 min and then washed with distilled
water and dried overnight. Colonies were counted using a
colony counter and plating efficiency and survival fraction
were calculated as follows: Plating efficiency (PE) = (num-
ber of colonies counted/number of cells plated)*100 and
Survival fraction (SF) = (PE of treated sample/PE of
control)*100.
Apoptosis analysis
Induction of apoptosis in human breast cancer cells caused
by resveratrol and pterostilbene treatment alone or in com-
bination was quantitatively determined by flow cytometry
using Annexin V-conjugated Alexafluro 488 (Alexa488)
Apoptosis Vybrant Assay Kit. Approximately 8 × 104
cells/2 ml were plated in 6-well plates. Medium con-
taining freshly added resveratrol (15 μM), pterostilbene
(5 μM) and combination of resveratrol + pterostilbene
(15+5 μM, respectively) was added for 72 h. Following
treatment, cells were collected from 6-well plates by
trypsinization, washed with PBS, and incubated with
Alexa488 and propidium iodide (PI) for cellular stain-
ing in Annexin-binding buffer at room temperature for
10 min in the dark. The stained cells were analyzed by
fluorescence-activated cell sorting (FACS) by using a
FACS-Caliber instrument (BD Biosciences) equipped
with Cell Quest 3.3 software.
Cell cycle analysis
Flow cytometric assays were performed to assess the effects
of resveratrol and pterostilbene alone or in combination on
breast cancer cells. Approximately 8 × 104 cells/2 ml were
plated in 6-well plates. Medium containing freshly added
resveratrol (15 μM), pterostilbene (5 μM) and combination
of resveratrol + pterostilbene (15+5 μM, respectively) was
added for 72 h. After treatment, cells were fixed using 70 %
ethanol overnight and then were washed, pelleted and re-
suspended in 0.04 mg/ml of PI, 0.1 % TritonX-100 and 100
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mg/mL RNase in PBS. Stained DNA contents were ana-
lyzed with flow cytometry.
Reverse transcription-polymerase chain reaction
RT-PCR was used to examine the expression of genes of
interest. RNA was extracted using RNeasy Kit (Qiagen,
Valencia, CA). One μg was reverse transcribed to cDNA
using a cDNA synthesis kit (Bio-Rad).
Real-time PCR
To determine the quantitative expression of genes of
interest, Real-time PCR was performed. After 72 h of
treatment with single as well as combination of two diet-
ary bioactive compounds, cells were harvested, RNA was
extracted and cDNA was prepared as described above.
Primers (Table 2) were obtained from Integrated DNA
Technologies, Inc. All the reactions were performed in
triplicate and SYBR green Supermix (Bio-Rad) was used
as fluorescent dye in Roche Light cycler 480. Thermal
cycling was initiated at 94 °C for 4 min followed by 35
cycles of PCR (94 °C, 15 s; 60 °C, 30 s; 72 °C, 30 s).
GAPDH was used as an endogenous control and vehicle
control was used as a calibrator. The relative changes in
gene expression were calculated using the following for-
mula: Fold change in gene expression, 2-ΔΔCt = 2-{ΔCt
(treated samples)-ΔCt (untreated control samples)}, where ΔCt = Ct
(genes of interest) – Ct (GAPDH) and Ct represents
threshold cycle number.
Western blotting
Protein extractions were performed by RIPA Lysis Buffer
(Upstate Biotechnology, Charlottesville, VA) according
to the manufacture’s protocol. Protein concentration was
further determined with the Bradford method of protein
quantification using the Bio-Rad Protein Assay (Bio-Rad;
Hercules, CA). About 50 μg of the whole cell protein ex-
tract were loaded onto a 4–15 % Tris–HCl gel (Bio-Rad)
and separated by electrophoresis at 150 V until the dye
front ran off the gel. Separated proteins were then
transferred to a nitrocellulose membrane using Trans-
Blot Turbo transfer system (Bio-Rad) at 25 V for 7 min.
After successful transfer, membranes were blocked in
0.5 % dry milk in Tris Buffered saline solution with 1 %
Tween (TBST) using SNAP i.d. protein detection system.
Primary and secondary antibody incubation was carried out
according to the manufacturer’s protocol. Membranes were
probed with the following monoclonal antibodies: SIRT1
(ABcam), Phospho H2AX (Cell signaling) and β-actin (Cell
signaling). Immunoreactive bands were visualized using the
Bio-Rad ChemiDoc XRS+ system.
Immunofluorescence (IF) microscopy
Cells were treated and plated for 72 h in small petri
plates (Corning®). After successful treatments, cells were
prepared for IF microscopy following cell signaling tech-
nology protocol. Primary monoclonal antibodies were
used for Phospho-H2AX (Cell signaling). Anti-Rabbit
IgG Alexa Fluor®488 conjugate (Cell Signaling) green
were used as secondary antibody. DAPI-blue (VECTA-
SHIELD) was used as antifade mounting medium. Pre-
pared samples were observed using NIKON AZ100M
microscope (in dark).
SIRT activity assay
Cultured breast cancer cells were harvested at the indi-
cated time points and nuclear extract was prepared using
nuclear extraction reagent (Pierce, Rockford, IL). The ac-
tivity of SIRT was performed according to the manufac-
turer’s protocol using Epigenase Universal SIRT activity/
Inhibition assay kit (EpigentecK, Brooklyn, NY).
DNMTs activity assay
DNA methyltransferases (DNMTs) are a family of en-
zymes that transfer a methyl group to DNA. Cultured
breast cancer cells were harvested at the indicated time
points and nuclear extract was prepared with the nuclear
extraction reagent (Pierce, Rockford, IL). Overall DNMT
activity was determined using the EpiQuik DNA Methyl-
transferase Activity Assay Kit (Epigentek) according to
the manufacture’s protocol. This analysis provides the
levels of overall DNMT activity and is not specific to any
particular gene or to any particular DNMT, and data are
represented in terms of percentage control.
Small interfering RNA (siRNA) knockdown
HCC1806 breast cancer cells were grown in 6-well plates
and allowed to incubate overnight. The SIRT1 siRNA was
obtained from Santa Cruz Biotechnology. After dilution
Table 2 Primer sequences, forward and reverse, used for realtime PCR analysis
Gene Forward primer Reverse primer
GAPDH 5′-ACC ACA GTC CAT GCC ATC AC-3′ 5′-TCC ACC CTG TTG CTG TA-3′
SIRT1 5′-TGG CAA AGG AGC AGA TTA GTA GG-3′ 5′-CTG CCA CAA GAA CTA GAG GAT AAG A-3′
DNMT1 5′-TAC CTG GAC GAC CCT GAC CTC-3′ 5′-CGT TGG CAT CAA AGA TGG ACA-3′
DNMT3A 5′-TAT TGA TGA GCG CAC AAG AGA GC-3′ 5′-GGG TGT TCC AGG GTA ACA TTG AGS′
DNMT3B 5′-GGC AAG TTC TCC GAG GTC TCT G-3′ 5′-TGG TAC ATG GCT TTT CGA TAG GAS′
hTERT 5′-AGG GGC AAG TCC TAC GTC CAG T-3′ 5′-CAC CAA CAA GAA ATC CAC C-3′
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with nuclease free water, 30 nM siRNA was delivered to
the cells using 3 μL of Silencer siRNA Transfection agent
(Ambion/Applied Biosystems, TX, USA) according to
the manufacturer’s instructions. Scrambled non-targeting
siRNA (Santa Cruz Biotechnology) was used as a negative
control to determine off-targets. After 72 h of knockdown,
cells were harvested and checked for knockdown using
RT-PCR and western blot.
Telomerase activity assay (TRAP)
Telomerase activity was measured using TeloTAGGG
telomerase PCR ELISA kit (Roche applied science, In-
dianapolis, IN) according to the manufacturer’s protocol.
Total protein (5 μg) was added to the reaction mixture,
and the generated telomere product was PCR amplified
using 30 cycles (25 °C for 20 min, 94 °C for 5 min, 94 °C
for 30 sec, 50 °C for 30 sec, 72 °C for 10 min). The amp-
lified PCR product (5 μL) was subjected to treatment for
the ELISA assay. The color change was measured within
30 min at 450 nm and with 690 nm as the reference
wavelength, using an ELISA plate reader (Bio-Rad).
Relative activity was measured in comparison to the
DMSO control.
Quantification of combination index
In order to determine the effects of combination of these
two compounds on breast cancer cells, CompuSyn software
was used. This software generates combination index (CI)
values which further assists determination of the nature of
the combination in comparison to single compound
effects. It is freely available at http://www.combosyn.-
com/feature.html. CI <1, CI = 1, CI >1 represent syn-
ergism, additivity, or antagonism, respectively.
Statistical analysis
All the data were determined from at least three inde-
pendent experiments. Statistical significance of differ-
ences between the values of treated samples and control
was determined by one way ANOVA using GraphPad
Prism version 4.00 for Windows, graphPad Software
(www.graphpad.com). In each case, p <0.05 and p <0.01
was considered statistically significant and highly signifi-
cant, respectively.
Additional files
Additional file 1: Is the report generated after using CompuSyn
software to calculate the synergism in HCC1806 breast cancer cells.
It reflects the 72 h MTT values and compares single dose treatment
with combination doses and determines the most effective
interaction and can be interpreted by combination index (CI) values.
CI values range from 0 to 1. The lower the CI values, the more
effective is the interaction and the stronger the synergism and vice
versa. (PDF 139 kb)
Additional file 2: Is the report generated after using CompuSyn
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